Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04752813 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

StatusActive, Not Recruiting
PhasePhase 2
SponsorBPGbio
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 26, 2026 (before its estimated August 25, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv13
  2. Primary completion date: Sep 24, 2025 to Aug 25, 2026 Trial status: Recruiting to Active, Not Recruiting · Study sites: 12 to 11 · Completion date: Dec 30, 2025 to Aug 26, 2030 · 2 morev12 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 12 to 11
    • Completion date: Dec 30, 2025 to Aug 26, 2030
    • Eligibility criteria expanded, about 46 words
    • Secondary endpoints: details revised at 1 of 2 entries

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 13 to 12v11
  4. Primary completion date: Feb 24, 2025 to Sep 24, 2025 Study sites: 9 to 13v10 Show 1 more changeShow less
    • Study sites: 9 to 13
  5. Study sites: 8 to 9v9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 6 to 8v8
  2. Primary completion date: Dec 24, 2025 to Feb 24, 2025 Completion date: May 30, 2026 to Dec 30, 2025 · Start date changed from estimate of Sep 28, 2023 to Aug 22, 2022 · Site details revised at 2 of 6 sitesv7 Show 3 more changesShow less
    • Completion date: May 30, 2026 to Dec 30, 2025
    • Start date changed from estimate of Sep 28, 2023 to Aug 22, 2022
    • Site details revised at 2 of 6 sites
  3. Primary completion date: Feb 2023 to Dec 24, 2025 Start date: Aug 2, 2021 to Sep 28, 2023 · Study sites: 4 to 6 · Completion date: Sep 2027 to May 30, 2026v6 Show 3 more changesShow less
    • Start date: Aug 2, 2021 to Sep 28, 2023
    • Study sites: 4 to 6
    • Completion date: Sep 2027 to May 30, 2026
  4. Site details revised at 3 of 4 sitesv5
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 5 to 4 · Start date changed from estimate of Jul 2021 to Aug 2, 2021v4 Show 2 more changesShow less
    • Study sites: 5 to 4
    • Start date changed from estimate of Jul 2021 to Aug 2, 2021
  6. Start date: May 2021 to Jul 2021v3
  7. Start date: Mar 2021 to May 2021 Primary endpoint revised · Enrollment target: 47 to 50 · Study sites: 4 to 5 · 1 morev2 Show 4 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 47 to 50
    • Study sites: 4 to 5
    • Secondary endpoints revised (2)

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BPGbio
3 trials monitored
See all monitored trials
Glioblastoma
670 trials monitored
See 44 trials at risk
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
Trial Details
NCT Number NCT04752813
Lead Sponsor BPGbio
Conditions Glioblastoma, Glioblastoma Multiforme
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov